How Have Orphan Drugs Changed the Specialty Landscape Over the Past Few Years?


 
Gilbert: I think orphan drugs have made significant changes to the specialty pharmacy landscape recently, specifically because some of these drugs are coming to disease states that have never had treatment before and also have extremely small patient population.
 
That requires us as specialty pharmacies to really be targeted and focused on those specific needs of those small patient populations, which are unique from other patient populations that we have dealt with in the past. 

Most Popular

Related Articles

The FDA has announced its approval of avatrombopag (Doptelet, AkaRx) tablets to treat low blood platelet count in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.
Antibiotic-resistant Acinetobacter baumannii infections put children with compromised immune systems in health care settings at greater risk of infections of the lung, urinary tract, and other sites.
Pharmacies are increasingly using collected health data to target advertising to customers or identify needs and purchase patterns.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.